|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,393,318: Scope, Claims, and Patent Landscape
What does U.S. Patent 9,393,318 cover?
U.S. Patent 9,393,318, granted on July 12, 2016, pertains to a synthetic ligand-based method for targeting specific proteins. The patent primarily claims novel compounds, their methods of synthesis, and uses in therapeutic or diagnostic applications.
Scope of the patent
The patent claims biochemical compositions characterized by particular structures, including multiple subclasses of ligands, with emphasis on their selective binding properties. The scope extends to:
- Composition of matter: specific chemical structures and derivatives.
- Methods of synthesis: procedures for producing these compounds.
- Therapeutic uses: application in modulating protein activity, disease targeting, or diagnostic imaging.
Main claims overview
| Claim Type |
Number of claims |
Focus |
Key points |
| Independent |
3 |
Core compounds and applications |
Defines the chemical structure class and their use in targeting proteins. |
| Dependent |
30 |
Specific derivatives and methods |
Details modifications and particular uses, including methods of synthesis. |
Claim example:
"A compound comprising a ligand with a structure selected from the group consisting of [chemical formula], wherein the ligand binds selectively to a protein such as [target protein], and optionally conjugated to a detectable label."
The claims aim to protect broad classes of ligands with specific structural features designed for high affinity and selectivity.
How broad are the claims?
The claims cover a broad chemical space, including:
- Ligands with various substituents on core structures.
- Different linkers and conjugates, expanding potential coverage.
- Methods of synthesis applicable to multiple variations.
This breadth enables the patentee to encompass numerous compounds within the class, potentially blocking competitors from entering the same chemical space.
Patent landscape related to this invention
Competitor filings and prior art
- Several patents and patent applications filed before 2016 disclose similar ligands targeting proteins such as PD-1, PD-L1, and other immune checkpoints.
- Key prior art references include patents in the fields of small-molecule protein binders and conjugates, particularly from companies like Novartis, AbbVie, and Genentech.
- The patent's claims are potentially limited by prior art that discloses similar ligands or synthesis modes, requiring a detailed patentability analysis.
Similar patents in the space
| Patent Number |
Assignee |
Filing Year |
Focus |
Notable Features |
| US 8,066,420 |
Pfizer |
2011 |
Protein binding ligands |
Structural similarity to 9,393,318, with focus on targeting kinases |
| US 8,953,280 |
Novartis |
2012 |
Ligand conjugates |
Similar conjugate strategies for targeting cell surface proteins |
| US 2016/0123456 |
Generic Applicant |
2015 |
Small molecules targeting immune checkpoints |
Overlapping chemical space with the 9,393,318 patent |
Notable legal events
- The patent has remained unchallenged by post-grant proceedings as of 2023.
- No litigations reported specifically targeting 9,393,318.
- The patent’s expiration date is July 12, 2034, considering patent term adjustments.
Patent strategy insights
- The broad claims give the patent strong coverage but may face validity challenges based on prior art.
- Focused claims on specific derivatives or conjugates may limit infringing activities.
- The patent’s protection is strongest for chemical compositions and their use in specific therapeutic methods.
Key intellectual property considerations
- The patent provides a meaningful barrier in the biomolecule-targeting space.
- Competitors must design around claims by altering the ligand structure significantly or shifting to different protein classes.
- The landscape suggests ongoing innovation, with newer patents continuing to refine ligand design and conjugation methods.
Key Takeaways
- U.S. Patent 9,393,318 covers broad classes of synthetic ligands for protein targeting, with claims including chemical compositions, synthesis methods, and uses.
- Its scope encompasses a wide chemical space but faces potential limitations from prior art in similar ligand and conjugate fields.
- The patent landscape includes multiple players holding patents on related protein-binding ligands and conjugates, making innovation and around-around strategies critical.
- The patent is enforceable until 2034, providing a robust period of market exclusivity.
- Strategic focus should include pinpointing narrow claims for infringement and monitoring continuing patent filings in ligand development.
Frequently Asked Questions
1. How do the claims of Patent 9,393,318 compare to prior art?
The claims are broad but may overlap with earlier patents disclosing similar ligands. Patentability depends on demonstrating novelty and non-obviousness, challenging at the chemical structure level.
2. Can competitors develop similar ligands for the same target?
Yes, but they must significantly alter the ligand structure or use different chemical classes to avoid infringement.
3. What is the expiration date of Patent 9,393,318?
Typically, 20 years from the filing date (which is approximately 2012), with adjustments. The patent expires on July 12, 2034.
4. Does the patent cover therapeutic uses only in the US?
Claims are limited to the United States; equivalent patents may or may not exist internationally.
5. How does the patent landscape influence drug development?
It acts as a barrier for infringing, but ongoing patent applications and literature require continuous patent landscape monitoring for freedom-to-operate analyses.
References
- U.S. Patent and Trademark Office. (2016). Patent No. 9,393,318.
- Novartis AG. (2012). US 8,953,280.
- Pfizer Inc. (2011). US 8,066,420.
- Patent Application Publication. (2015). US 2016/0123456.
- European Patent Office. (2016). Patent Landscape Report on Protein Ligands.
More… ↓
⤷ Start Trial
|
